Nuveen
RCUS icon

Nuveen’s Arcus Biosciences RCUS Stock Holding History

Nuveen’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.22M Buy
234,052
+12,342
+6% +$305K ﹤0.01% 1898
2026
Q1 		$4.79M Buy
221,710
+80,110
+57% +$1.73M ﹤0.01% 1906
2025
Q4 		$3.37M Buy
141,600
+14,762
+12% +$301K ﹤0.01% 2085
2025
Q3 		$1.72M Hold
126,838
– – ﹤0.01% 2356
2025
Q2 		$1.03M Sell
126,838
-5,021
-4% -$42.9K ﹤0.01% 2590
2025
Q1 		$1.04M Hold
131,859
– – ﹤0.01% 2631
2024
Q4 		$1.96M Sell
131,859
-37,994
-22% -$620K ﹤0.01% 2398
2024
Q3 		$2.6M Buy
169,853
+2,552
+2% +$40.2K ﹤0.01% 2294
2024
Q2 		$2.55M Buy
167,301
+40,082
+32% +$647K ﹤0.01% 2266
2024
Q1 		$2.4M Sell
127,219
-6,228
-5% -$108K ﹤0.01% 2312
2023
Q4 		$2.55M Sell
133,447
-330,476
-71% -$5.28M ﹤0.01% 2301
2023
Q3 		$8.33M Buy
463,923
+5,780
+1% +$116K ﹤0.01% 1583
2023
Q2 		$9.3M Buy
458,143
+16,902
+4% +$322K ﹤0.01% 1563
2023
Q1 		$8.05M Buy
441,241
+298,925
+210% +$5.71M ﹤0.01% 1622
2022
Q4 		$2.94M Sell
142,316
-24,359
-15% -$670K ﹤0.01% 2205
2022
Q3 		$4.36M Sell
166,675
-4,956
-3% -$131K ﹤0.01% 1981
2022
Q2 		$4.35M Sell
171,631
-86,371
-33% -$2.12M ﹤0.01% 2036
2022
Q1 		$8.93M Sell
258,002
-1,224
-0.5% -$41K ﹤0.01% 1720
2021
Q4 		$10.1M Sell
259,226
-18,817
-7% -$730K ﹤0.01% 1688
2021
Q3 		$10.1M Sell
278,043
-147,031
-35% -$4.58M ﹤0.01% 1773
2021
Q2 		$11.7M Buy
425,074
+253,089
+147% +$7.23M ﹤0.01% 1771
2021
Q1 		$4.83M Sell
171,985
-32,804
-16% -$1.14M ﹤0.01% 2187
2020
Q4 		$5.32M Sell
204,789
-11,563
-5% -$280K ﹤0.01% 2042
2020
Q3 		$3.71M Sell
216,352
-65,075
-23% -$1.45M ﹤0.01% 2077
2020
Q2 		$6.96M Buy
281,427
+45,307
+19% +$1.22M ﹤0.01% 1715
2020
Q1 		$3.28M Buy
236,120
+49,958
+27% +$621K ﹤0.01% 1937
2019
Q4 		$1.88M Buy
186,162
+45,707
+33% +$384K ﹤0.01% 2441
2019
Q3 		$1.28M Buy
140,455
+6,962
+5% +$55.9K ﹤0.01% 2593
2019
Q2 		$1.06M Buy
+133,493
New +$1.34M ﹤0.01% 2708

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Nuveen's RCUS Position: Q2 2026 in Review

Nuveen increased its Arcus Biosciences (RCUS) stake by 5.6% in Q2 2026, buying an estimated $305K and bringing the position to 234,052 shares worth $7.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1898.

Nuveen first reported a position in RCUS in Q2 2019 and has held it in 29 quarters since. The position peaked at $11.7M in Q2 2021. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Nuveen held 234,052 shares of Arcus Biosciences worth $7.22M as of Q2 2026.
  • Nuveen bought 12,342 Arcus Biosciences shares in Q2 2026, an estimated $305K.
  • Arcus Biosciences made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1898 holding.
  • Nuveen first reported a position in Arcus Biosciences in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Arcus Biosciences position peaked at $11.7M in Q2 2021.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.